Skip to main content
Top
Published in: Drug Safety 2/2002

01-02-2002 | Review Article

Effects of Psychotropic Drugs on Seizure Threshold

Authors: Professor Francesco Pisani, Giancarla Oteri, Cinzia Costa, Giorgio Di Raimondo, Raoul Di Perri

Published in: Drug Safety | Issue 2/2002

Login to get access

Abstract

Psychotropic drugs, especially antidepressants and antipsychotics, may give rise to some concern in clinical practice because of their known ability to reduce seizure threshold and to provoke epileptic seizures. Although the phenomenon has been described with almost all the available compounds, neither its real magnitude nor the seizurogenic potential of individual drugs have been clearly established so far. In large investigations, seizure incidence rates have been reported to range from ∼0.1 to ∼1.5% in patients treated with therapeutic doses of most commonly used antidepressants and antipsychotics (incidence of the first unprovoked seizure in the general population is 0.07 to 0.09%). In patients who have taken an overdose, the seizure risk rises markedly, achieving values of ∼4 to ∼30%. This large variability, probably due to methodological differences among studies, makes data confusing and difficult to interpret. Agreement, however, converges on the following: seizures triggered by psychotropic drugs are a dose-dependent adverse effect; maprotiline and clomipramine among antidepressants and chlorpromazine and clozapine among antipsychotics that have a relatively high seizurogenic potential; phenelzine, tranylcypromine, fluoxetine, paroxetine, sertraline, venlafaxine and trazodone among antidepressants and fluphenazine, haloperidol, pimozide and risperidone among antipsychotics that exhibit a relatively low risk. Apart from drug-related factors, seizure precipitation during psychotropic drug medication is greatly influenced by the individual’s inherited seizure threshold and, particularly, by the presence of seizurogenic conditions (such as history of epilepsy, brain damage, etc.). Pending identification of compounds with less or no effect on seizure threshold and formulation of definite therapeutic guidelines especially for patients at risk for seizures, the problem may be minimised through careful evaluation of the possible presence of seizurogenic conditions and simplification of the therapeutic scheme (low starting doses/slow dose escalation, maintenance of the minimal effective dose, avoidance of complex drug combinations, etc.). Although there is sufficient evidence that psychotropic drugs may lower seizure threshold, published literature data have also suggested that an appropriate psychotropic therapy may not only improve the mental state in patients with epilepsy, but also exert antiepileptic effects through a specific action. Further scientific research is warranted to clarify all aspects characterising the complex link between seizure threshold and psychotropic drugs.
Literature
1.
go back to reference Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981 Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981
2.
go back to reference Edwards JG, Long KS, Sedgwick EM, et al. Antidepressants and convulsive seizures: clinical, electroencephalographic and pharmacological aspects. Clin Neuropharm 1986; 9: 329–60CrossRef Edwards JG, Long KS, Sedgwick EM, et al. Antidepressants and convulsive seizures: clinical, electroencephalographic and pharmacological aspects. Clin Neuropharm 1986; 9: 329–60CrossRef
3.
go back to reference Robertson MM. The organic contribution to depressive illness in patients with epilepsy. J Epilepsy 1989; 2: 189–223CrossRef Robertson MM. The organic contribution to depressive illness in patients with epilepsy. J Epilepsy 1989; 2: 189–223CrossRef
4.
go back to reference Matthews WS, Barabas G. Suicide and epilepsy: a review of the literature. Psychosomatics 1981; 22: 515–24PubMed Matthews WS, Barabas G. Suicide and epilepsy: a review of the literature. Psychosomatics 1981; 22: 515–24PubMed
5.
go back to reference Anton-Stephens D. Preliminary observations on the psychiatric use of chlorpromazine. J Ment Sci 1953; 100: 543–7 Anton-Stephens D. Preliminary observations on the psychiatric use of chlorpromazine. J Ment Sci 1953; 100: 543–7
6.
go back to reference Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959; 105: 1123–6PubMed Leyberg JT, Denmark JC. The treatment of depressive states with imipramine hydrochloride (Tofranil). J Ment Sci 1959; 105: 1123–6PubMed
7.
go back to reference Blair D. Treatment of severe depression by imipramine: an investigation of 100 cases. J Ment Sci 1960; 106: 891–905 Blair D. Treatment of severe depression by imipramine: an investigation of 100 cases. J Ment Sci 1960; 106: 891–905
8.
go back to reference Sharp WL. Convulsions associated with anti-depressant drugs. Am J Psychiatry 1960; 117: 458–9 Sharp WL. Convulsions associated with anti-depressant drugs. Am J Psychiatry 1960; 117: 458–9
9.
go back to reference Kiloh LG, Davison K, Ossleton JW. An electroencephalographic study on the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961; 12: 165–72 Kiloh LG, Davison K, Ossleton JW. An electroencephalographic study on the analeptic effects of imipramine. Electroencephalogr Clin Neurophysiol 1961; 12: 165–72
10.
go back to reference Davison K. EEG activation after intravenous amitriptyline. Electroencephalogr Clin Neurophysiol 1965; 19: 298–300PubMedCrossRef Davison K. EEG activation after intravenous amitriptyline. Electroencephalogr Clin Neurophysiol 1965; 19: 298–300PubMedCrossRef
11.
go back to reference Redding FK. EEG activation with amitriptyline. Electroencephalogr Clin Neurophysiol 1969; 26: 630–6CrossRef Redding FK. EEG activation with amitriptyline. Electroencephalogr Clin Neurophysiol 1969; 26: 630–6CrossRef
12.
go back to reference Legg NJ, Swash M. Clinical note: seizures and EEG activation after trimipramine. Epilepsia 1974; 15: 131–5PubMedCrossRef Legg NJ, Swash M. Clinical note: seizures and EEG activation after trimipramine. Epilepsia 1974; 15: 131–5PubMedCrossRef
13.
go back to reference Rumpl E, Hinterhuber H. Unusual spike-wave stupor in a patient with manic-depressive psychosis treated with amitriptyline. J Neurol 1981; 226: 131–5PubMedCrossRef Rumpl E, Hinterhuber H. Unusual spike-wave stupor in a patient with manic-depressive psychosis treated with amitriptyline. J Neurol 1981; 226: 131–5PubMedCrossRef
14.
go back to reference Meldrum B, Anlezark G, Trimble M. Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsy in papio papio. Eur J Pharmacol 1975; 32: 203–13PubMedCrossRef Meldrum B, Anlezark G, Trimble M. Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsy in papio papio. Eur J Pharmacol 1975; 32: 203–13PubMedCrossRef
15.
go back to reference Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1–66PubMedCrossRef Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975; 16: 1–66PubMedCrossRef
16.
go back to reference Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiat 1983; 44: 197–201 Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiat 1983; 44: 197–201
17.
go back to reference Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressant and convulsions. J Clin Pharmacol 1983; 3: 182–5 Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressant and convulsions. J Clin Pharmacol 1983; 3: 182–5
18.
go back to reference Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99PubMed Rosenstein DL, Nelson JC, Jacobs SC. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99PubMed
19.
go back to reference Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86–90PubMedCrossRef Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression: a perspective on seizures. Arch Gen Psychiatry 1986; 43: 86–90PubMedCrossRef
20.
go back to reference Physician’s Desk Reference. Prozac. Montvale (NJ): Medical Economics, 1992: 921 Physician’s Desk Reference. Prozac. Montvale (NJ): Medical Economics, 1992: 921
21.
go back to reference Edwards JG, Inman WHW, Wilton L, et al. Prescription-event monitoring of 10401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387–95PubMedCrossRef Edwards JG, Inman WHW, Wilton L, et al. Prescription-event monitoring of 10401 patients treated with fluvoxamine. Br J Psychiatry 1994; 164: 387–95PubMedCrossRef
22.
go back to reference Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77PubMedCrossRef Logothetis J. Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77PubMedCrossRef
23.
24.
go back to reference Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247–9PubMedCrossRef Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247–9PubMedCrossRef
25.
go back to reference Stimmel GL, Dopheide JA. Psychotropic drug-induced reductions in seizure threshold: incidence and consequences. CNS Drugs 1996; 5: 37–50CrossRef Stimmel GL, Dopheide JA. Psychotropic drug-induced reductions in seizure threshold: incidence and consequences. CNS Drugs 1996; 5: 37–50CrossRef
26.
go back to reference Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999; 53Suppl. 2: 68–75 Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999; 53Suppl. 2: 68–75
27.
go back to reference Quitkin F, Rifkin A, Klein DF. Very high dosage versus standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975; 32: 1276–81PubMedCrossRef Quitkin F, Rifkin A, Klein DF. Very high dosage versus standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975; 32: 1276–81PubMedCrossRef
28.
29.
go back to reference Leber P. Adverse drug reactions -‘time-less’ risks (a hazard of risk assessment: the example of seizure and antidepressants). Psychopharmacol Bull 1985; 21: 334–8PubMed Leber P. Adverse drug reactions -‘time-less’ risks (a hazard of risk assessment: the example of seizure and antidepressants). Psychopharmacol Bull 1985; 21: 334–8PubMed
30.
go back to reference Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991; 9(1): 37–52PubMed Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991; 9(1): 37–52PubMed
31.
go back to reference Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93–4CrossRef Lewis JA. Post-marketing surveillance: how many patients? Trends Pharmacol Sci 1981; 2: 93–4CrossRef
32.
go back to reference Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19: 696–700PubMedCrossRef Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19: 696–700PubMedCrossRef
33.
go back to reference Delay J, Deniker P. Efficacy of Tofranil in the treatment of various types of depression: a comparison with other antidepressant drugs. Can Psychiatr Ass J 1959; 4: 100–12 Delay J, Deniker P. Efficacy of Tofranil in the treatment of various types of depression: a comparison with other antidepressant drugs. Can Psychiatr Ass J 1959; 4: 100–12
34.
go back to reference Freyhan FA. Clinical effectiveness of Tofranil in the treatment of depressive psychoses. Can Psychiatr Ass J 1959; 4: 86–9 Freyhan FA. Clinical effectiveness of Tofranil in the treatment of depressive psychoses. Can Psychiatr Ass J 1959; 4: 86–9
35.
go back to reference Burley DM. A brief note on the problem of epilepsy in antidepressant treatment. In: Jukes A, editor. Depression: the biochemical and physiologic role of Ludiomil. Horsham (UK): Ciba, 1977: 201–3 Burley DM. A brief note on the problem of epilepsy in antidepressant treatment. In: Jukes A, editor. Depression: the biochemical and physiologic role of Ludiomil. Horsham (UK): Ciba, 1977: 201–3
36.
go back to reference Jabbari B, Bryan G, Mars LE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1PubMedCrossRef Jabbari B, Bryan G, Mars LE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1PubMedCrossRef
37.
go back to reference Lowry MR, Dunner FJ. Seizures during tricyclic therapy. Am J Psychat 1980; 137: 1461–2 Lowry MR, Dunner FJ. Seizures during tricyclic therapy. Am J Psychat 1980; 137: 1461–2
38.
go back to reference Jus A, Villeneuve A, Gautier J, et al. Influence of lithium carbonate on patients with temporal epilepsy. Can Psychiatr Assoc J 1973; 18: 77–8PubMed Jus A, Villeneuve A, Gautier J, et al. Influence of lithium carbonate on patients with temporal epilepsy. Can Psychiatr Assoc J 1973; 18: 77–8PubMed
39.
go back to reference Betts TA, Kalra PL, Cooper R, et al. Epileptic fits as a probable side-effect of amitriptyline: report of seven cases. Lancet 1968; I: 390–2CrossRef Betts TA, Kalra PL, Cooper R, et al. Epileptic fits as a probable side-effect of amitriptyline: report of seven cases. Lancet 1968; I: 390–2CrossRef
40.
41.
go back to reference Edwards JG, Glen-Bott M. Mianserin and convulsive seizures. Br J Clin Pharmacol 1983; 15: 299–311CrossRef Edwards JG, Glen-Bott M. Mianserin and convulsive seizures. Br J Clin Pharmacol 1983; 15: 299–311CrossRef
42.
go back to reference Alldredge BK. Drug induced seizures: controversies in their identification and management. Pharmacotherapy 1997; 17: 857–60PubMed Alldredge BK. Drug induced seizures: controversies in their identification and management. Pharmacotherapy 1997; 17: 857–60PubMed
43.
go back to reference Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8PubMedCrossRef Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8PubMedCrossRef
44.
go back to reference Michals ML, Crismon ML, Roberts S, et al. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993; 13: 198–203PubMedCrossRef Michals ML, Crismon ML, Roberts S, et al. Clozapine response and adverse effects in nine brain-injured patients. J Clin Psychopharmacol 1993; 13: 198–203PubMedCrossRef
45.
go back to reference Franson KL, Hay DP, Neppe V, et al. Drug-induced seizures in the elderly: causative agents and optimal management. Drugs Aging 1995; 7(1): 38–48PubMedCrossRef Franson KL, Hay DP, Neppe V, et al. Drug-induced seizures in the elderly: causative agents and optimal management. Drugs Aging 1995; 7(1): 38–48PubMedCrossRef
46.
go back to reference Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379–84PubMedCrossRef Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997; 96: 379–84PubMedCrossRef
47.
48.
go back to reference Physicians’ desk reference. Montvale (NJ): Medical Economics, 1999 Physicians’ desk reference. Montvale (NJ): Medical Economics, 1999
49.
go back to reference Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52: 1323–9PubMedCrossRef Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem Pharmacol 1996; 52: 1323–9PubMedCrossRef
50.
go back to reference Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatr Bull 1995; 19: 355–7CrossRef Duncan D, Taylor D. Which is the safest antidepressant to use in epilepsy? Psychiatr Bull 1995; 19: 355–7CrossRef
51.
go back to reference Trimble MR. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1978; 19: 241–50PubMedCrossRef Trimble MR. Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review. Epilepsia 1978; 19: 241–50PubMedCrossRef
52.
go back to reference Starkey IR, Lawson AA. Poisoning with tricyclic and related antidepressant: a ten year review. Q J Med 1980; 193: 33–49 Starkey IR, Lawson AA. Poisoning with tricyclic and related antidepressant: a ten year review. Q J Med 1980; 193: 33–49
53.
go back to reference Biggs JT, Spiker DG, Petit JM, et al. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977; 238: 135–8PubMedCrossRef Biggs JT, Spiker DG, Petit JM, et al. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977; 238: 135–8PubMedCrossRef
54.
55.
go back to reference Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160–2PubMed Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160–2PubMed
56.
go back to reference Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment. Clin Neuropharmacol 1987; 10: 265–7CrossRef Pascual J, Combarros O, Berciano J. Partial status epilepticus following single low dose of chlorimipramine in a patient on MAO-inhibitor treatment. Clin Neuropharmacol 1987; 10: 265–7CrossRef
57.
go back to reference Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tryciclic antidepressant and lithium treatment. J Clin Psychopharm 1988; 8: 446–7CrossRef Devanand DP, Sackeim HA, Brown RP. Myoclonus during combined tryciclic antidepressant and lithium treatment. J Clin Psychopharm 1988; 8: 446–7CrossRef
58.
go back to reference Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol 1996; 3: 272–4PubMedCrossRef Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol 1996; 3: 272–4PubMedCrossRef
59.
go back to reference DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997; 19: 71–3PubMedCrossRef DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997; 19: 71–3PubMedCrossRef
60.
go back to reference Miyata H, Kubota F, Shibata N, et al. Non-convulsive status epilepticus induced by antidepressants. Seizure 1997; 6(5): 405–7PubMedCrossRef Miyata H, Kubota F, Shibata N, et al. Non-convulsive status epilepticus induced by antidepressants. Seizure 1997; 6(5): 405–7PubMedCrossRef
61.
go back to reference Zivin L, Ajmone Marsan C. Incidence and prognostic significance of ‘epileptiform’ activity in the EEG of non-epileptic subjects. Brain 1968; 91: 751–77PubMedCrossRef Zivin L, Ajmone Marsan C. Incidence and prognostic significance of ‘epileptiform’ activity in the EEG of non-epileptic subjects. Brain 1968; 91: 751–77PubMedCrossRef
62.
go back to reference Reilly EL, Reed K, Kelley JT. EEG and psychotropic drugs. In: Hughes JR, Wilson WP, editors. EEG and evoked potentials in psychiatry and behavioral neurology. Boston: Butterworths, 1983: 79–99 Reilly EL, Reed K, Kelley JT. EEG and psychotropic drugs. In: Hughes JR, Wilson WP, editors. EEG and evoked potentials in psychiatry and behavioral neurology. Boston: Butterworths, 1983: 79–99
63.
go back to reference Sedgwick EM, Edwards JG. Mianserin, maprotiline and the electroencephalogram. Br J Clin Pharmacol 1983; 15: 255–62CrossRef Sedgwick EM, Edwards JG. Mianserin, maprotiline and the electroencephalogram. Br J Clin Pharmacol 1983; 15: 255–62CrossRef
64.
go back to reference Itil TM. Psychotropic drugs and the human EEG. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 499–513 Itil TM. Psychotropic drugs and the human EEG. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 499–513
65.
go back to reference Aguglia U, Gambardella A, Le Piane E, et al. Chlorpromazine versus sleep deprivation in activation of EEG in adult-onset partial epilepsy. J Neurol 1994; 241: 605–10PubMedCrossRef Aguglia U, Gambardella A, Le Piane E, et al. Chlorpromazine versus sleep deprivation in activation of EEG in adult-onset partial epilepsy. J Neurol 1994; 241: 605–10PubMedCrossRef
66.
go back to reference Toone BK, Fenton GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977; 7: 265–70PubMedCrossRef Toone BK, Fenton GW. Epileptic seizures induced by psychotropic drugs. Psychol Med 1977; 7: 265–70PubMedCrossRef
67.
go back to reference Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 1984; 25: 25–32PubMedCrossRef Luchins DJ, Oliver AP, Wyatt RJ. Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 1984; 25: 25–32PubMedCrossRef
68.
go back to reference Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures: an in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982; 39(2): 206–9PubMedCrossRef Oliver AP, Luchins DJ, Wyatt RJ. Neuroleptic-induced seizures: an in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982; 39(2): 206–9PubMedCrossRef
69.
go back to reference Bauer G. EEG, drug effects, and central nervous system poisoning. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 479–89 Bauer G. EEG, drug effects, and central nervous system poisoning. In: Niedermeyer E, Lopes da Silva F, editors. Electroencephalography: basic principles, clinical applications and related fields. Baltimore: Urban & Schwarzenberg, 1982: 479–89
70.
go back to reference Fink M. EEG profiles and bioavailability measures of psychoactive drugs. Mod Probl Pharmacopsychiatry 1974; 8: 76–98 Fink M. EEG profiles and bioavailability measures of psychoactive drugs. Mod Probl Pharmacopsychiatry 1974; 8: 76–98
71.
go back to reference Herrmann WM, Schaerer E. Pharmaco-EEG: computer EEG analysis to describe the projection of drug effects on a functional cerebral level in humans. In: Lopes da Silva FH, Storm van Leeuwen W, Remond A, editors. Handbook of electroencephalography and clinical neurophysiology, revised series. Vol. 2. Amsterdam: Elsevier, 1986: 385–445 Herrmann WM, Schaerer E. Pharmaco-EEG: computer EEG analysis to describe the projection of drug effects on a functional cerebral level in humans. In: Lopes da Silva FH, Storm van Leeuwen W, Remond A, editors. Handbook of electroencephalography and clinical neurophysiology, revised series. Vol. 2. Amsterdam: Elsevier, 1986: 385–445
72.
go back to reference Glaze DG. Drug effects. In: Daly DD, Pedley TA, editors. Current practice of clinical electroencephalography. 2nd ed. New York: Raven Press, 1990: 489–512 Glaze DG. Drug effects. In: Daly DD, Pedley TA, editors. Current practice of clinical electroencephalography. 2nd ed. New York: Raven Press, 1990: 489–512
73.
go back to reference Helmchen H, Kanowski S. EEG changes under lithium (Li) treatment. Electroencephalogr Clin Neurophysiol 1971; 30: 269PubMed Helmchen H, Kanowski S. EEG changes under lithium (Li) treatment. Electroencephalogr Clin Neurophysiol 1971; 30: 269PubMed
74.
go back to reference Small JG. EEG and lithium CNS toxicity. Am J EEG Technol 1986; 26: 225–39 Small JG. EEG and lithium CNS toxicity. Am J EEG Technol 1986; 26: 225–39
75.
go back to reference Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6: 250–6PubMed Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6: 250–6PubMed
76.
go back to reference Neufeld MY, Rabey JM, Orlov E, et al. Electroencephalographic findings with low-dose clozapine treatment in psychotic parkinsonian patients. Clin Neuropharmacol 1996; 19(1): 81–6PubMedCrossRef Neufeld MY, Rabey JM, Orlov E, et al. Electroencephalographic findings with low-dose clozapine treatment in psychotic parkinsonian patients. Clin Neuropharmacol 1996; 19(1): 81–6PubMedCrossRef
77.
go back to reference Freudenreich O, Richard D, McEvoy W, et al. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42: 132–7PubMedCrossRef Freudenreich O, Richard D, McEvoy W, et al. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42: 132–7PubMedCrossRef
78.
go back to reference Schuld A, Kuhn M, Haack M, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry 2000; 33: 109–11PubMedCrossRef Schuld A, Kuhn M, Haack M, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry 2000; 33: 109–11PubMedCrossRef
79.
go back to reference Pillmann F, Schlote K, Broich K, et al. Electroencephalogram alterations during treatment with olanzapine. Psychopharmacology 2000; 150: 216–9PubMedCrossRef Pillmann F, Schlote K, Broich K, et al. Electroencephalogram alterations during treatment with olanzapine. Psychopharmacology 2000; 150: 216–9PubMedCrossRef
80.
go back to reference Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8: 296–8PubMed Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8: 296–8PubMed
81.
82.
go back to reference Trabert W, Hohagen F, Winkelmann G, et al. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995; 28: 95–7PubMedCrossRef Trabert W, Hohagen F, Winkelmann G, et al. A seizure, and electroencephalographic signs of a lowered seizure threshold, associated with fluvoxamine treatment of obsessive-compulsive disorder. Pharmacopsychiatry 1995; 28: 95–7PubMedCrossRef
83.
go back to reference Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35: 237–40PubMedCrossRef Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997; 35: 237–40PubMedCrossRef
84.
go back to reference Atril PB, Julius DA. Maprotile hydrochloride associated with a clinical state of catatonic stupor and epileptic encephalogram. J Clin Psychopharmacol 1984; 4: 207–9 Atril PB, Julius DA. Maprotile hydrochloride associated with a clinical state of catatonic stupor and epileptic encephalogram. J Clin Psychopharmacol 1984; 4: 207–9
85.
go back to reference Trimble MR. New antidepressant drugs and the seizure threshold. Neuropharmacology 1980; 19: 1227–8PubMedCrossRef Trimble MR. New antidepressant drugs and the seizure threshold. Neuropharmacology 1980; 19: 1227–8PubMedCrossRef
86.
go back to reference Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy [letter]. Arch Gen Psych 1985; 42: 523CrossRef Lefkowitz D, Kilgo G, Lee S. Seizures and trazodone therapy [letter]. Arch Gen Psych 1985; 42: 523CrossRef
88.
go back to reference Schindler BA, Ramcandani D. Partial complex status epilepticus in a lithium-toxic patient. Psychosomatics 1993; 4: 521–4CrossRef Schindler BA, Ramcandani D. Partial complex status epilepticus in a lithium-toxic patient. Psychosomatics 1993; 4: 521–4CrossRef
89.
go back to reference Showron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18–22 Showron DM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18–22
90.
go back to reference Remick RA, Fine SH. Antipsychotic drugs and seizures. J Clin Psychiatry 1979; 40(2): 78–80PubMed Remick RA, Fine SH. Antipsychotic drugs and seizures. J Clin Psychiatry 1979; 40(2): 78–80PubMed
91.
go back to reference Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987; 9(2): 135–41PubMedCrossRef Markowitz JC, Brown RP. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987; 9(2): 135–41PubMedCrossRef
92.
93.
go back to reference Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy: a double-blind trial. J Affect Disord 1985; 9: 127–36PubMedCrossRef Robertson MM, Trimble MR. The treatment of depression in patients with epilepsy: a double-blind trial. J Affect Disord 1985; 9: 127–36PubMedCrossRef
94.
go back to reference Itil TM, Myers JP. Epileptic and anti-epileptic properties of psychotropic drugs. In: Mercier J, editor. Anticonvulsant drugs. International encyclopedia of pharmacology and therapeutics. Vol. 19, No. 2. Oxford: Pergamon, 1973: 599–622 Itil TM, Myers JP. Epileptic and anti-epileptic properties of psychotropic drugs. In: Mercier J, editor. Anticonvulsant drugs. International encyclopedia of pharmacology and therapeutics. Vol. 19, No. 2. Oxford: Pergamon, 1973: 599–622
95.
go back to reference Itil TM. Convulsive and anticonvulsive properties of neuropsychopharmaca. In: Niederland E, editor. Epilepsy: modern problems of pharmacopsychiatry. Vol. 4. New York: Karger, 1970: 270–305 Itil TM. Convulsive and anticonvulsive properties of neuropsychopharmaca. In: Niederland E, editor. Epilepsy: modern problems of pharmacopsychiatry. Vol. 4. New York: Karger, 1970: 270–305
96.
go back to reference Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95CrossRef Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95CrossRef
97.
go back to reference Frommer DA, Kulig KW, Marx GA, et al. Tricyclic antidepressant overdose: a review. JAMA 1987; 257: 521–6PubMedCrossRef Frommer DA, Kulig KW, Marx GA, et al. Tricyclic antidepressant overdose: a review. JAMA 1987; 257: 521–6PubMedCrossRef
98.
99.
go back to reference Olson KR, Kearney TE, Dver JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12: 392–5PubMedCrossRef Olson KR, Kearney TE, Dver JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994; 12: 392–5PubMedCrossRef
100.
go back to reference Preskorn SH, Othmer SC, Lai CW, et al. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. J Clin Psychopharmacol 1984; 4: 262–4PubMedCrossRef Preskorn SH, Othmer SC, Lai CW, et al. Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations. J Clin Psychopharmacol 1984; 4: 262–4PubMedCrossRef
101.
go back to reference Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313: 474–9PubMedCrossRef Boehnert MT, Lovejoy FH. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313: 474–9PubMedCrossRef
102.
go back to reference Darby JK, Pasta DJ, Dabiri L, et al. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995; 15(5): 334–40PubMedCrossRef Darby JK, Pasta DJ, Dabiri L, et al. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995; 15(5): 334–40PubMedCrossRef
103.
go back to reference Richens A, Nawishy S, Trimble MR. Antidepressant drugs, convulsions, and epilepsy. Br J Clin Pharmacol 1983; 15: 295–8CrossRef Richens A, Nawishy S, Trimble MR. Antidepressant drugs, convulsions, and epilepsy. Br J Clin Pharmacol 1983; 15: 295–8CrossRef
104.
go back to reference Perucca E, Manzo L, Crema A. Pharmacokinetic interaction between antiepileptic and psychotropic drugs. In: Trimble MR, editor. The psychopharmacology of epilepsy: Chichester: John Wiley & Sons, 1985: 95–105 Perucca E, Manzo L, Crema A. Pharmacokinetic interaction between antiepileptic and psychotropic drugs. In: Trimble MR, editor. The psychopharmacology of epilepsy: Chichester: John Wiley & Sons, 1985: 95–105
105.
go back to reference Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479–87CrossRef Spina E, Perucca E. Newer and older antidepressants: a comparative review of drug interactions. CNS Drugs 1994; 2: 479–87CrossRef
106.
go back to reference Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999; 40(10 Suppl): 71S–6SCrossRef Monaco F, Cicolin A. Interactions between anticonvulsant and psychoactive drugs. Epilepsia 1999; 40(10 Suppl): 71S–6SCrossRef
107.
go back to reference Baldessarini RJ, Teicher MH, Cassidy JW. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988; 8: 381–2PubMedCrossRef Baldessarini RJ, Teicher MH, Cassidy JW. Anticonvulsant cotreatment may increase toxic metabolites of antidepressants and other psychotropic drugs. J Clin Psychopharmacol 1988; 8: 381–2PubMedCrossRef
108.
go back to reference Troupin AS, Ojemann LM. Paradoxical intoxication: a complication of anticonvulsant administration. Epilepsia 1975; 16: 753–8PubMedCrossRef Troupin AS, Ojemann LM. Paradoxical intoxication: a complication of anticonvulsant administration. Epilepsia 1975; 16: 753–8PubMedCrossRef
109.
go back to reference Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3 Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3
110.
go back to reference Dersun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993; 342: 442–3CrossRef Dersun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993; 342: 442–3CrossRef
111.
go back to reference Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992; 55: 412–3PubMedCrossRef Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992; 55: 412–3PubMedCrossRef
112.
113.
go back to reference Fenton GJ. Psychiatric disorders of epilepsy: classification and phenomelogy. In: Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981: 12–26 Fenton GJ. Psychiatric disorders of epilepsy: classification and phenomelogy. In: Reynolds EH, Trimble MR, editors. Epilepsy and psychiatry. Edinburgh: Churchill Livingstone, 1981: 12–26
114.
go back to reference Perrine K, Congett S. Neurobehavioral problems in epilepsy. Neurol Clin 1994; 12: 129–52PubMed Perrine K, Congett S. Neurobehavioral problems in epilepsy. Neurol Clin 1994; 12: 129–52PubMed
115.
go back to reference Pauig PM, Deluca MA, Osterheld RG. Thioridazine hydrochloride in the treatment of behavior disorders in epileptics. Am J Psychiatry 1961; 117: 832–3PubMed Pauig PM, Deluca MA, Osterheld RG. Thioridazine hydrochloride in the treatment of behavior disorders in epileptics. Am J Psychiatry 1961; 117: 832–3PubMed
116.
go back to reference Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepine on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8PubMedCrossRef Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepine on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8PubMedCrossRef
117.
go back to reference Millichap JG. Anticonvulsant drugs. In: Root WS, Hofmann FG, editors. Physiological pharmacology: a comprehensive treatise. New York: Academic Press, 1965: 97–173 Millichap JG. Anticonvulsant drugs. In: Root WS, Hofmann FG, editors. Physiological pharmacology: a comprehensive treatise. New York: Academic Press, 1965: 97–173
118.
119.
go back to reference Fromm GH, Rosen JA, Amores CY. A clinical and experimental investigation of the effect of imipramine on epilepsy. Epilepsia 1971; 12: 282–3 Fromm GH, Rosen JA, Amores CY. A clinical and experimental investigation of the effect of imipramine on epilepsy. Epilepsia 1971; 12: 282–3
120.
go back to reference Fromm GH, Wessel HB, Glass JD, et al. Imipramine in absence and myoclonic-astatic seizures. Neurology 1978; 28: 953–7PubMedCrossRef Fromm GH, Wessel HB, Glass JD, et al. Imipramine in absence and myoclonic-astatic seizures. Neurology 1978; 28: 953–7PubMedCrossRef
121.
go back to reference Setiey A, Courjon J. Clomipramine et petit mal. Lyon Med 1978; 239: 751–4 Setiey A, Courjon J. Clomipramine et petit mal. Lyon Med 1978; 239: 751–4
122.
go back to reference Sakakihara Y, Oka A, Kubota M, et al. Reduction of seizure frequency with clomipramine in patients with complex partial seizures. Brain Dev 1995; 17: 291–3PubMedCrossRef Sakakihara Y, Oka A, Kubota M, et al. Reduction of seizure frequency with clomipramine in patients with complex partial seizures. Brain Dev 1995; 17: 291–3PubMedCrossRef
123.
go back to reference Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995; 45: 1926–7PubMedCrossRef Favale E, Rubino V, Mainardi P, et al. Anticonvulsant effect of fluoxetine in humans. Neurology 1995; 45: 1926–7PubMedCrossRef
124.
go back to reference Lange SC, Julien RM, Fowler GW. Biphasic effects of imipramine in experimental models of epilepsy. Epilepsia 1976; 17: 183–96PubMedCrossRef Lange SC, Julien RM, Fowler GW. Biphasic effects of imipramine in experimental models of epilepsy. Epilepsia 1976; 17: 183–96PubMedCrossRef
125.
go back to reference Vernier VG. The pharmacology of antidepressant agents. Dis Nerv Syst 1961; 22: 7–13PubMed Vernier VG. The pharmacology of antidepressant agents. Dis Nerv Syst 1961; 22: 7–13PubMed
126.
go back to reference Chen G, Ensor CR, Bohner B. Studies of drug effects on electrically induced extensor seizures and clinical implications. Arch Int Pharmacodyn Ther 1968; 172: 183–218PubMed Chen G, Ensor CR, Bohner B. Studies of drug effects on electrically induced extensor seizures and clinical implications. Arch Int Pharmacodyn Ther 1968; 172: 183–218PubMed
127.
go back to reference Stille G, Sayers A. The effect of antidepressant drugs on the convulsive excitability of brain structures. Int J Neuropharmacol 1964; 3: 605–9PubMedCrossRef Stille G, Sayers A. The effect of antidepressant drugs on the convulsive excitability of brain structures. Int J Neuropharmacol 1964; 3: 605–9PubMedCrossRef
128.
go back to reference Meldrum BS, Anlezark GM, Adam HK, et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology 1982; 76: 212–7PubMedCrossRef Meldrum BS, Anlezark GM, Adam HK, et al. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology 1982; 76: 212–7PubMedCrossRef
129.
go back to reference Woods TW, Jobe PC, Laird HE, et al. Anticonvulsant and proconvulsant doses of desipramine in the genetically epilepsyprone rat. Fed Proc 1983; 42: 363 Woods TW, Jobe PC, Laird HE, et al. Anticonvulsant and proconvulsant doses of desipramine in the genetically epilepsyprone rat. Fed Proc 1983; 42: 363
130.
go back to reference Woods TW, Dailey JW, Reigel CE, et al. Anticonvulsant and proconvulsant effects of doxepin in genetically epilepsy prone rat (GEPR). Fed Proc 1985; 44: 1107 Woods TW, Dailey JW, Reigel CE, et al. Anticonvulsant and proconvulsant effects of doxepin in genetically epilepsy prone rat (GEPR). Fed Proc 1985; 44: 1107
131.
go back to reference Emori K, Minabe Y, Tanii Y, et al. Effects of chronic treatment with haloperidol and methamphetamine on hippocampal kindled seizures in the cat. Epilepsy Res 1991; 8(3): 213–9PubMedCrossRef Emori K, Minabe Y, Tanii Y, et al. Effects of chronic treatment with haloperidol and methamphetamine on hippocampal kindled seizures in the cat. Epilepsy Res 1991; 8(3): 213–9PubMedCrossRef
132.
go back to reference George B, Kulkarni SK. Protective effect of clozapine against pentylenetetrazol convulsions and kindling. Meth Find Exp Clin Pharmacol 1998; 20(5): 395–401CrossRef George B, Kulkarni SK. Protective effect of clozapine against pentylenetetrazol convulsions and kindling. Meth Find Exp Clin Pharmacol 1998; 20(5): 395–401CrossRef
133.
go back to reference Koella WP, Glatt A, Klebs K, et al. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine and amitriptyline. Biol Psychiatry 1979; 14: 485–97PubMed Koella WP, Glatt A, Klebs K, et al. Epileptic phenomena induced in the cat by the antidepressants maprotiline, imipramine, clomipramine and amitriptyline. Biol Psychiatry 1979; 14: 485–97PubMed
134.
go back to reference Jobe PC, Woods TW, Dailey JW. Pro-convulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. In: Porter RJ, Mattson J, Richard H, et al., editors. Advances in epileptology: 15th Epilepsy International Symposium. New York: Raven Press, 1984: 187–91 Jobe PC, Woods TW, Dailey JW. Pro-convulsant and anticonvulsant effects of tricyclic antidepressants in genetically epilepsy-prone rats. In: Porter RJ, Mattson J, Richard H, et al., editors. Advances in epileptology: 15th Epilepsy International Symposium. New York: Raven Press, 1984: 187–91
135.
go back to reference Marescaux C, Hirsch E, Fink S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990; 31: 768–77PubMedCrossRef Marescaux C, Hirsch E, Fink S, et al. Landau-Kleffner syndrome: a pharmacologic study of five cases. Epilepsia 1990; 31: 768–77PubMedCrossRef
136.
137.
go back to reference Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1487–9PubMedCrossRef Shields WD, Saslow E. Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1487–9PubMedCrossRef
138.
go back to reference Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3 Johnsen SD, Tarby TJ, Sidell AD. Carbamazepine-induced seizures. Ann Neurol 1984; 16: 392–3
139.
go back to reference Snead OC, Hosey LN. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916–21PubMedCrossRef Snead OC, Hosey LN. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916–21PubMedCrossRef
140.
go back to reference Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology 1992; 42: 2198–201PubMedCrossRef Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure, and transient MRI abnormalities. Neurology 1992; 42: 2198–201PubMedCrossRef
141.
go back to reference Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate [letter]. Lancet 1982; I: 1306CrossRef Eeg-Olofsson O, Lindskog U. Acute intoxication with valproate [letter]. Lancet 1982; I: 1306CrossRef
142.
go back to reference Koenig SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new cases. Epilepsia 1994; 35: 1005–15CrossRef Koenig SA, Siemes H, Blaker F, et al. Severe hepatotoxicity during valproate therapy: an update and report of eight new cases. Epilepsia 1994; 35: 1005–15CrossRef
143.
go back to reference Chadwick DW, Cumming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979; 6: 552–3PubMedCrossRef Chadwick DW, Cumming WJK, Livingstone I, et al. Acute intoxication with sodium valproate. Ann Neurol 1979; 6: 552–3PubMedCrossRef
144.
go back to reference Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972; 13: 421–35PubMedCrossRef Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972; 13: 421–35PubMedCrossRef
145.
go back to reference Prior PF, Maclaine GN, Scott DF, et al. Tonic status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia 1972; 13: 467–72PubMedCrossRef Prior PF, Maclaine GN, Scott DF, et al. Tonic status epilepticus precipitated by intravenous diazepam in a child with petit mal status. Epilepsia 1972; 13: 467–72PubMedCrossRef
146.
go back to reference Bittencourt PRM, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1991; 22: 129–34CrossRef Bittencourt PRM, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1991; 22: 129–34CrossRef
147.
go back to reference Di Mario Jr FJ, Calancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988; 4: 249–51CrossRef Di Mario Jr FJ, Calancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988; 4: 249–51CrossRef
148.
go back to reference Alvarez N, Hartford E, Doubt C. Epileptic seizures induced by clonazepam. Clin Electroencephal 1981; 12: 57–65 Alvarez N, Hartford E, Doubt C. Epileptic seizures induced by clonazepam. Clin Electroencephal 1981; 12: 57–65
149.
go back to reference Neufeld MY. Exacerbation of focal seizures due to carbamazepine treatment in an adult patient. Clin Neuropharmacol 1993; 16: 359–61PubMedCrossRef Neufeld MY. Exacerbation of focal seizures due to carbamazepine treatment in an adult patient. Clin Neuropharmacol 1993; 16: 359–61PubMedCrossRef
150.
go back to reference Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5–17PubMedCrossRef Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39: 5–17PubMedCrossRef
151.
go back to reference Trimble MR, Anlezark G, Meldrum BS. Seizure activity in photosensitive baboons following antidepressant drugs and the role of serotonergic mechanisms. Psychopharmacology 1977; 51: 159–64PubMedCrossRef Trimble MR, Anlezark G, Meldrum BS. Seizure activity in photosensitive baboons following antidepressant drugs and the role of serotonergic mechanisms. Psychopharmacology 1977; 51: 159–64PubMedCrossRef
152.
go back to reference Altshuler HL, Killam EK, Killam KF. Biogenic amines and the photo-myoclonic syndrome in the baboon, papio papio. J Pharmacol Exp Ther 1976; 196: 156–66PubMed Altshuler HL, Killam EK, Killam KF. Biogenic amines and the photo-myoclonic syndrome in the baboon, papio papio. J Pharmacol Exp Ther 1976; 196: 156–66PubMed
153.
go back to reference Chadwick D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977; 1: 218–24PubMedCrossRef Chadwick D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977; 1: 218–24PubMedCrossRef
154.
go back to reference Snead OC. On the sacred disease: the neurochemistry of epilepsy. Int Rev Neurobiol 1983; 24: 93–180PubMedCrossRef Snead OC. On the sacred disease: the neurochemistry of epilepsy. Int Rev Neurobiol 1983; 24: 93–180PubMedCrossRef
155.
go back to reference Deahl M, Trimble MR. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991; 159: 433–5PubMedCrossRef Deahl M, Trimble MR. Serotonin reuptake inhibitors, epilepsy and myoclonus. Br J Psychiatry 1991; 159: 433–5PubMedCrossRef
156.
go back to reference Wada Y, Nakamura M, Hasegowa H, et al. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992; 141: 21–4PubMedCrossRef Wada Y, Nakamura M, Hasegowa H, et al. Role of serotonin receptor subtype in seizures kindled from the feline hippocampus. Neurosci Lett 1992; 141: 21–4PubMedCrossRef
157.
go back to reference Dailey JW, Reith ME, Steidley KR, et al. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998; 39: 1054–63PubMedCrossRef Dailey JW, Reith ME, Steidley KR, et al. Carbamazepine-induced release of serotonin from rat hippocampus in vitro. Epilepsia 1998; 39: 1054–63PubMedCrossRef
158.
go back to reference Dailey JW, Yan QS, Adams-Curtis LE, et al. Neurochemical correlates of antiepileptic drugs in the genetically epilepsyprone rat (GEPR). Life Sci 1996; 58: 259–66PubMedCrossRef Dailey JW, Yan QS, Adams-Curtis LE, et al. Neurochemical correlates of antiepileptic drugs in the genetically epilepsyprone rat (GEPR). Life Sci 1996; 58: 259–66PubMedCrossRef
159.
go back to reference Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34(4): 275–81PubMedCrossRef Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995; 34(4): 275–81PubMedCrossRef
160.
go back to reference Sackeim HA, Decina P, Prohovnik I, et al. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983; 18: 1301–10PubMed Sackeim HA, Decina P, Prohovnik I, et al. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry 1983; 18: 1301–10PubMed
161.
go back to reference Post RM, Putnam F, Uhde TW, et al. Electroconvulsive therapy as an anticonvulsant: implications for its mechanism of action in affective illness. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. Ann NY Acad Sci 1986; 462: 376–88 Post RM, Putnam F, Uhde TW, et al. Electroconvulsive therapy as an anticonvulsant: implications for its mechanism of action in affective illness. In: Malitz S, Sackeim HA, editors. Electroconvulsive therapy: clinical and basic research issues. Ann NY Acad Sci 1986; 462: 376–88
162.
go back to reference Coffey CE, Lucke J, Weiner RD, et al. Seizure threshold in electroconvulsive therapy (ECT) II: the anticonvulsant effect of ECT. Biol Psychiatry 1995; 37: 777–88PubMedCrossRef Coffey CE, Lucke J, Weiner RD, et al. Seizure threshold in electroconvulsive therapy (ECT) II: the anticonvulsant effect of ECT. Biol Psychiatry 1995; 37: 777–88PubMedCrossRef
163.
go back to reference Harmant J, van Rijckevorsel-Harmant K, DeBarsy T, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect [letter]. Lancet 1990; 336: 386PubMedCrossRef Harmant J, van Rijckevorsel-Harmant K, DeBarsy T, et al. Fluvoxamine: an antidepressant with low (or no) epileptogenic effect [letter]. Lancet 1990; 336: 386PubMedCrossRef
164.
go back to reference Reynolds EH. The pharmacological management of epilepsy associated with psychological disorders. Br J Psychiat 1982; 141: 549–57CrossRef Reynolds EH. The pharmacological management of epilepsy associated with psychological disorders. Br J Psychiat 1982; 141: 549–57CrossRef
165.
go back to reference Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994; 39(4): 236–8PubMed Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994; 39(4): 236–8PubMed
166.
go back to reference Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50PubMedCrossRef Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapidcycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11): 841–50PubMedCrossRef
Metadata
Title
Effects of Psychotropic Drugs on Seizure Threshold
Authors
Professor Francesco Pisani
Giancarla Oteri
Cinzia Costa
Giorgio Di Raimondo
Raoul Di Perri
Publication date
01-02-2002
Publisher
Springer International Publishing
Published in
Drug Safety / Issue 2/2002
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225020-00004

Other articles of this Issue 2/2002

Drug Safety 2/2002 Go to the issue